CareDx Inc (NASDAQ:CDNA) has priced its underwritten public offering of around 4.341 million shares at a price of $4 per share. In addition, the firm granted the underwriters a 30-day alternative to buy up to 651,240 additional shares to meet over-allotments, if any. The firm anticipates to close the public offering on or about October 9, 2017, depending on the closure of customary closing conditions. H.C. Wainwright & Co. is the co-manager for the offering while Craig-Hallum Capital Group is sole book-running manager.
CareDx expects the aggregate net proceeds will be around $15.9 million, after subtracting the underwriting discounts and commissions and projected offering expenses payable by the firm, but discounting any exercise of the underwriters’ alternative to buy additional shares. The firm plans to use the net proceeds from the public offering for general corporate purposes and working capital.
Earlier in the last week of September, CareDx reported that it has obtained notice that the Molecular Diagnostics Services Program advanced by Palmetto GBA has fixed AlloSure reimbursement at $2,840.75. AlloSure will be repaid for kidney transplant patients protected by Medicare across the U.S. starting October 9, 2017. Around 80% of kidney transplant patients are offered cover by Medicare. Payments will be done by Noridian, which has executed the MolDX Plan and is the Medicare administrator in company’s jurisdiction.
Medicare repayment for AlloSure follows a demanding technical assessment by the MolDX Plan. Evidence in favor of the AlloSure test comprised a clinical study in 400 patients and 14 major transplant centers with follow-up over eighteen months. A potential observational cohort trial will start in early 2018 to offer more data on longer term results, as part of an exposure under data development obligation.
In the last trading session, the stock price of CareDx jumped more than 31% to close the day at $5.82.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.